Characterization of Protective Immune Responses Induced by Pneumococcal Surface Protein A in Fusion with Pneumolysin Derivatives

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Goulart, Cibelly ^a,b   Silva, Thais Raquel da ^c   Rodriguez, Dunia ^a   Politano, Walter Rodrigo ^c   Leite, Luciana C C ^a,b   Darrieux, Michelle ^c  

^a INSTITUTO BUTANTAN   (Brazil)

^b Instituto de Pesquisas Tecnologicas   (Brazil)

^c UNIVERSIDADE SÃO FRANCISCO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BACTERIAL PROTEIN; COMPLEMENT COMPONENT C3; PNEUMOCOCCAL SURFACE PROTEIN A1 ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A1 PROTEIN P1D1 ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A1 PROTEIN P1D2 ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A2 ANTIBODY; PNEUMOCOCCAL SURFACE PROTEIN A2 PNEUMOLYSOID T ANTIBODY; PNEUMOCOCCUS VACCINE; PNEUMOLYSOID T ANTIBODY; PROTEIN P1D1 ANTIBODY; PROTEIN P1D2 ANTIBODY; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A1; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A1 PLD1 FUSION PROTEIN; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A1 PLD2 FUSION PROTEIN; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A2; RECOMBINANT PNEUMOCOCCAL SURFACE PROTEIN A2 PNEUMOLYSOID T FUSION PROTEIN; RECOMBINANT PNEUMOLYSOID T; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN PLD1; RECOMBINANT PROTEIN PLD2; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; BACTERIAL GENE; BACTERICIDAL ACTIVITY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; CROSS REACTION; CYTOLYSIS; DRUG EFFICACY; DRUG PURIFICATION; GENE FUSION; GENETIC IMMUNIZATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; OPSONOPHAGOCYTOSIS; PHAGOCYTOSIS; PLY GENE; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL SURFACE PROTEIN A1 PLD1 GENE; PNEUMOCOCCAL SURFACE PROTEIN A1 PLD2 GENE; PNEUMOCOCCAL SURFACE PROTEIN A2 PNEUMOLYSOID T GENE; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SURVIVAL;

ANIMALS; BACTERIAL PROTEINS; FEMALE; MICE; MICE, INBRED BALB C; PNEUMOCOCCAL VACCINES; RECOMBINANT FUSION PROTEINS; STREPTOLYSINS;

EID: 84875304782     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0059605     Document Type: Article

References (49)

1. O'Brien KL, Wolfson LJ, Watt JP, Henkle E, Deloria-Knoll M, et al. (2009) Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374: 893-902.
2. Singleton RJ, Hennessy TW, Bulkow LR, Hammitt LL, Zulz T, et al. (2007) Invasive pneumococcal disease caused by nonvaccine serotypes among alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297: 1784-1792.
3. Hsu HE, Shutt KA, Moore MR, Beall BW, Bennett NM, et al. (2009) Effect of pneumococcal conjugate vaccine on pneumococcal meningitis. N Engl J Med 360: 244-256.
4. Song JH, Dagan R, Klugman KP, Fritzell B, (2012) The relationship between pneumococcal serotypes and antibiotic resistance. Vaccine 30: 2728-2737.
5. Ogunniyi AD, LeMessurier KS, Graham RM, Watt JM, Briles DE, et al. (2007) Contributions of pneumolysin, pneumococcal surface protein A (PspA), and PspC to pathogenicity of Streptococcus pneumoniae D39 in a mouse model. Infect Immun 75: 1843-1851.
6. Berry AM, Paton JC, (2000) Additive attenuation of virulence of Streptococcus pneumoniae by mutation of the genes encoding pneumolysin and other putative pneumococcal virulence proteins. Infect Immun 68: 133-140.
7. Quin LR, Moore QC 3rd, McDaniel LS (2007) Pneumolysin, PspA, and PspC contribute to pneumococcal evasion of early innate immune responses during bacteremia in mice. Infect Immun 75: 2067-2070.
8. Ren B, Szalai AJ, Hollingshead SK, Briles DE, (2004) Effects of PspA and antibodies to PspA on activation and deposition of complement on the pneumococcal surface. Infect Immun 72: 114-122.
9. Tu AH, Fulgham RL, McCrory MA, Briles DE, Szalai AJ, (1999) Pneumococcal surface protein A inhibits complement activation by Streptococcus pneumoniae. Infect Immun 67: 4720-4724.
10. McDaniel LS, Ralph BA, McDaniel DO, Briles DE, (1994) Localization of protection-eliciting epitopes on PspA of Streptococcus pneumoniae between amino acid residues 192 and 260. Microb Pathog 17: 323-337.
11. Moreno AT, Oliveira ML, Ferreira DM, Ho PL, Darrieux M, et al. (2010) Immunization of mice with single PspA fragments induces antibodies capable of mediating complement deposition on different pneumococcal strains and cross-protection. Clinical and vaccine immunology: CVI 17: 439-446.
12. Roche H, Hakansson A, Hollingshead SK, Briles DE, (2003) Regions of PspA/EF3296 best able to elicit protection against Streptococcus pneumoniae in a murine infection model. Infect Immun 71: 1033-1041.
13. Darrieux M, Miyaji EN, Ferreira DM, Lopes LM, Lopes AP, et al. (2007) Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun 75: 5930-5938.
14. Briles DE, Hollingshead SK, Paton JC, Ades EW, Novak L, et al. (2003) Immunizations with pneumococcal surface protein A and pneumolysin are protective against pneumonia in a murine model of pulmonary infection with Streptococcus pneumoniae. J Infect Dis 188: 339-348.
15. Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE,et al. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog 48: 205-213.
16. Arulanandam BP, Lynch JM, Briles DE, Hollingshead S, Metzger DW, (2001) Intranasal vaccination with pneumococcal surface protein A and interleukin-12 augments antibody-mediated opsonization and protective immunity against Streptococcus pneumoniae infection. Infect Immun 69: 6718-6724.
17. Kono M, Hotomi M, Hollingshead SK, Briles DE, Yamanaka N, (2011) Maternal immunization with pneumococcal surface protein A protects against pneumococcal infections among derived offspring. PLoS One 6: e27102.
18. Hollingshead SK, Becker R, Briles DE, (2000) Diversity of PspA: mosaic genes and evidence for past recombination in Streptococcus pneumoniae. Infect Immun 68: 5889-5900.
19. Csordas FC, Perciani CT, Darrieux M, Goncalves VM, Cabrera-Crespo J, et al. (2008) Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine 26: 2925-2929.
20. Goulart C, Darrieux M, Rodriguez D, Pimenta FC, Brandileone MC, et al. (2011) Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine 29: 1634-1642.
21. Briles DE, Hollingshead SK, King J, Swift A, Braun PA, et al. (2000) Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. The Journal of infectious diseases 182: 1694-1701.
22. Marriott HM, Mitchell TJ, Dockrell DH, (2008) Pneumolysin: a double-edged sword during the host-pathogen interaction. Curr Mol Med 8: 497-509.
23. Marriott HM, Dockrell DH, (2006) Streptococcus pneumoniae: the role of apoptosis in host defense and pathogenesis. Int J Biochem Cell Biol 38: 1848-1854.
24. Srivastava A, Henneke P, Visintin A, Morse SC, Martin V, et al. (2005) The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 73: 6479-6487.
25. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100: 1966-1971.
26. Witzenrath M, Pache F, Lorenz D, Koppe U, Gutbier B, et al. (2011) The NLRP3 inflammasome is differentially activated by pneumolysin variants and contributes to host defense in pneumococcal pneumonia. J Immunol 187: 434-440.
27. Alexander JE, Lock RA, Peeters CC, Poolman JT, Andrew PW, et al. (1994) Immunization of mice with pneumolysin toxoid confers a significant degree of protection against at least nine serotypes of Streptococcus pneumoniae. Infect Immun 62: 5683-5688.
28. Kirkham LA, Kerr AR, Douce GR, Paterson GK, Dilts DA, et al. (2006) Construction and immunological characterization of a novel nontoxic protective pneumolysin mutant for use in future pneumococcal vaccines. Infect Immun 74: 586-593.
29. Ferreira DM, Areas AP, Darrieux M, Leite LC, Miyaji EN, (2006) DNA vaccines based on genetically detoxified derivatives of pneumolysin fail to protect mice against challenge with Streptococcus pneumoniae. FEMS Immunol Med Microbiol 46: 291-297.
30. Paton JC, Lock RA, Lee CJ, Li JP, Berry AM, et al. (1991) Purification and immunogenicity of genetically obtained pneumolysin toxoids and their conjugation to Streptococcus pneumoniae type 19F polysaccharide. Infect Immun 59: 2297-2304.
31. Wu K, Zhang X, Shi J, Li N, Li D, et al. (2010) Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae Infections in Mice. Infect Immun 78: 1276-1283.
32. Salha D, Szeto J, Myers L, Claus C, Sheung A, et al. (2012) Neutralizing antibodies elicited by a novel detoxified pneumolysin derivative, PlyD1, provide protection against both pneumococcal infection and lung injury. Infect Immun 80: 2212-2220.
33. Denoel P, Philipp MT, Doyle L, Martin D, Carletti G, et al. (2011) A protein-based pneumococcal vaccine protects rhesus macaques from pneumonia after experimental infection with Streptococcus pneumoniae. Vaccine 29: 5495-5501.
34. Berry AM, Alexander JE, Mitchell TJ, Andrew PW, Hansman D, et al. (1995) Effect of defined point mutations in the pneumolysin gene on the virulence of Streptococcus pneumoniae. Infect Immun 63: 1969-1974.
35. Ogunniyi AD, Grabowicz M, Briles DE, Cook J, Paton JC, (2007) Development of a vaccine against invasive pneumococcal disease based on combinations of virulence proteins of Streptococcus pneumoniae. Infect Immun 75: 350-357.
36. Ogunniyi AD, Folland RL, Briles DE, Hollingshead SK, Paton JC, (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68: 3028-3033.
37. Ramos CR, Abreu PA, Nascimento AL, Ho PL, (2004) A high-copy T7 Escherichia coli expression vector for the production of recombinant proteins with a minimal N-terminal His-tagged fusion peptide. Braz J Med Biol Res 37: 1103-1109.
38. Rodrigues DC, Cavada BS, Abreu-De-Oliveira JT, Moreira RA, Russo M, (1992) Differences in Macrophagesstimulation and leukocyte Accumulation in response to Intraperitoneal administration of Glucose/Mannose-Binding Plant Lectins. Brazilian J Med Biol Res 25: 823-826.
39. Xin W, Li Y, Mo H, Roland KL, Curtiss R 3rd (2009) PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun 77: 4518-4528.
40. Nguyen CT, Kim SY, Kim MS, Lee SE, Rhee JH, (2011) Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 29: 5731-5739.
41. Oliveira ML, Miyaji EN, Ferreira DM, Moreno AT, Ferreira PC, et al. (2010) Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS One 5: e10863.
42. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R, (2009) Protection against Pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun 77: 2076-2083.
43. Ljutic B, Ochs M, Messham B, Ming M, Dookie A, et al. (2012) Formulation, stability and immunogenicity of a trivalent pneumococcal protein vaccine formulated with aluminum salt adjuvants. Vaccine 30: 2981-2988.
44. Ogunniyi AD, Folland RL, Briles DB, Hollingshead SK, Paton JC, (2000) Immunization of mice with combinations of pneumococcal virulence proteins elicits enhanced protection against challenge with Streptococcus pneumoniae. Infect Immun 68: 3028-3033.
45. Price KE, Camilli A, (2009) Pneumolysin localizes to the cell wall of Streptococcus pneumoniae. J Bacteriol 191: 2163-2168.
46. Price KE, Greene NG, Camilli A, (2012) Export Requirements of Pneumolysin in Streptococcus pneumoniae. J Bacteriol 194: 3651-3660.
47. Berry AM, Lock RA, Hansman D, Paton JC, (1989) Contribution of autolysin to virulence of Streptococcus pneumoniae. Infect Immun 57: 2324-2330.
48. Balachandran P, Hollingshead SK, Paton JC, Briles DE, (2001) The autolytic enzyme LytA of Streptococcus pneumoniae is not responsible for releasing pneumolysin. J Bacteriol 183: 3108-3116.
49. Malley R, Henneke P, Morse SC, Cieslewicz MJ, Lipsitch M, et al. (2003) Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci U S A 100: 1966-1971.